Analyst Joseph Schwartz of Leerink Partners reiterated a Buy rating on Pharvaris, retaining the price target of $28.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Joseph Schwartz’s rating is based on several promising developments within Pharvaris. The company is making significant progress in its hereditary angioedema (HAE) platform, particularly with its oral small-molecule antagonist, deucrictibant. The RAPIDe-3 study data, which is crucial for on-demand treatment, is expected to be available by the fourth quarter of 2025, positioning Pharvaris for a potential New Drug Application submission in the first half of 2026 and a possible market launch in early 2027. This progress is complemented by the ongoing enrollment in the CHAPTER-3 study for prophylactic treatment, with results anticipated in the second half of 2026.
Additionally, Pharvaris has strengthened its financial position, ending the second quarter of 2025 with €200 million in cash and cash equivalents, further bolstered by a $201 million offering. This financial stability extends their operational runway into the first half of 2027, providing a solid foundation for future growth. The combination of these strategic advancements and a robust balance sheet underpins Schwartz’s optimistic outlook and Buy rating for Pharvaris.
In another report released on August 13, Citizens JMP also maintained a Buy rating on the stock with a $52.00 price target.
PHVS’s price has also changed moderately for the past six months – from $17.370 to $21.430, which is a 23.37% increase.